Alar Pharmaceuticals Achieves Significant Progress in Ketamine Therapy for Depression Treatment Alar Pharmaceuticals has received positive Phase 1 results for ALA-3000, a long-acting injectable ketamine aimed at treatment-resistant depression, promising better patient outcomes.

Alar Pharmaceuticals Achieves Significant Progress in Ketamine Therapy for Depression Treatment #Taiwan #Taichung #Ketamine_Therapy #Alar_Pharmaceuticals #ALA-3000

Alar Pharmaceuticals Introduces ALA-1000, a Breakthrough Injectable for Canine Osteoarthritis Management Alar Pharmaceuticals has announced the successful trial of ALA-1000, an injectable treatment for canine osteoarthritis that offers both long-term efficacy and safety.

Alar Pharmaceuticals Introduces ALA-1000, a Breakthrough Injectable for Canine Osteoarthritis Management #Taiwan #Taichung #Alar_Pharmaceuticals #ALA-1000 #Canine_Osteoarthritis